

TECHNOLOGY AND INNOVATION

ABOUT US

In 1898, eminent surgeon Dr. Roswell Park established the world's first institution dedicated to cancer research and created a powerful force by bringing together the knowledge and skills of pathologists, chemists, biologists, surgeons and other experts – all in one center.

His vision built a dynamic research engine that became a model for other cancer centers around the world.



SurVaxM
treatment vaccine
for glioblastoma



World's first
clinical trial using
**two-gene
combination**
for T-cell
engineering



OUR HISTORY OF SUCCESS

Our focus on cancer has unleashed more than a century of discovery and innovation that led to many game-changers in the fight against cancer, including:

- **PSA screening test** for prostate cancer
- **RPMI 1640 culture medium** used worldwide
- **Photodynamic therapy**
- **Photochlor**, a next-generation photosensitizing drug
- **5-FU + leucovorin therapy**, now the standard of care for colorectal cancer
- **RoSS simulator to train** robotic surgeons
- **OmniSeq**, a suite of diagnostics to match patients with treatment options based on comprehensive genomic sequencing and immune profiling
- **Prolivy**, a targeted immunotherapy for lymphoma



more than
170
available technologies

awarded
88
U.S. patents

104
license agreements

661
current clinical trials

14 biotech spinoff companies formed as a result of our discoveries and innovations



4 drugs/devices developed here received FDA approval

WHAT WE OFFER

We understand the challenges of moving novel technologies from the bench to the bedside and we are eager to work with industry partners and entrepreneurs to advance cancer treatment.



Our industry partnering activities and translational research model speed the progress of promising ideas from one phase of research to the next, through clinical trials that accelerate new treatments from the lab to the patients who need them.

TOMORROW'S NEW CELLULAR THERAPY, CANCER DRUG, DIAGNOSTIC, OR SURGICAL DEVICE MAY ALREADY BE HERE.

OUR TECHNOLOGIES

AVAILABLE
TECHNOLOGIES
BY TYPE



WE HAVE MORE THAN

170 INNOVATIONS

ready for advancement, development, licensing, and transfer to the marketplace, such as these novel approaches for:

OVARIAN CANCER	Novel armed CAR-T therapy
ESOPHAGEAL CANCER	Targeting glucose-stimulated phosphohistidine signaling
HER2 POSITIVE CANCERS	Treating with prolidase

CONTACT US

Patrick Emmerling, PhD, MBA, CLP

Director of Technology Transfer & Commercial Development

Patrick.Emmerling@RoswellPark.org

716-845-1300 x6955

